We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





World's First Confirmed Case of COVID-19 Re-Infection Raises Questions Over Coronavirus Immunity

By HospiMedica International staff writers
Posted on 27 Aug 2020
Researchers have reported the world’s first confirmed case of COVID-19 re-infection, raising questions about the durability of immune protection from the SARS-CoV-2 virus.

Researchers have confirmed that a 33-year-old man was first infected by SARS-CoV-2 in late March and then again contracted the virus after four and a half months while traveling in Europe, according to a report by STAT. More...
There have been reports earlier of cases of COVID-19 re-infection, although they were based on anecdotal evidence and had been attributed mainly to flaws in testing. However, in this latest case of COVID-19 re-infection, researchers from the University of Hong Kong (Hong Kong) sequenced the virus from the patient’s two infections and found that they did not match, indicating that the second infection was not linked to the first. The researchers found a difference of 24 nucleotides, the “letters” that make up the virus’ RNA, between the two infections.

The finding of the world’s first confirmed case of COVID-19 re-infection comes amidst concerns over how long one can remain protected from the SARS-CoV-2 virus after being infected and recovering. Various studies have found that the majority of recovered COVID-19 patients generate a robust immune response involving both antibodies (molecules that can block the virus from infecting cells again) and T cells (which can help clear the virus), according to the STAT report. This indicates protection from repeat COVID-19 infection could last for some time. However, experts believe that immunity to SARS-CoV-2 cannot last forever as people generally once again become susceptible to the coronaviruses that cause common cold after a year or even less, and remain protected against SARS-1 and MERS for just a few years.

Nevertheless, experts believe that the Hong Kong case is rare and unprecedented among the tens of millions of cases globally and immune protection to COVID-19 may generally last more than a few months. More definitive conclusions could be reached only after the conclusion of studies currently tracking patients who have recovered from COVID-19. Additionally, experts have pointed out that that the Hong Kong man’s second case was milder than his first, indicating that his immune system was providing some protection against the SARS-CoV-2 virus, even if it failed to prevent re-infection entirely, according to STAT.

“There’s been more than 24 million cases reported to date,” Maria Van Kerkhove, a coronavirus expert at the World Health Organization, said at a briefing, when asked about the Hong Kong report. “And we need to look at something like this at a population level. What we are learning about infection is that people do develop an immune response, and what is not completely clear yet is how strong that immune response is and for how long that immune response lasts.”

Related Links:
University of Hong Kong


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.